Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

liraglutide

AstraZeneca AZ

AZ sells rare cancer drug to Sanofi

French firm’s rare disease unit Genzyme will pay $300m for the treatment

- PMLiVE

David Khougazian appointed president of Sanofi Pasteur MSD

He will succeed Dr Jean-Paul Kress atthe Sanofi Pasteur - Merck & Co venture

- PMLiVE

Amgen beats Sanofi to PCSK9 inhibitor market

EC approval for Repatha gives it a lead over Praluent

- PMLiVE

Brandicourt steers Sanofi onto a new heading

Unveilsmajor restructuring of the French pharma group

- PMLiVE

Novo Nordisk’s next-gen GLP-1 aces late-stage trial

Firm hopes semaglutide will shore up future sales of its diabetes range

- PMLiVE

Novo pulls Tresiba from Europe’s biggest market

Firm’s new insulin will not be sold in Germany

- PMLiVE

US expands recommended use of meningitis B vaccines

Butopts not to back routine use of GSK's Bexsero and Pfizer' Trumenba

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Former Sanofi UK MD to head Teva UK

Steve Oldfield has been named as the firm’s new general manager

- PMLiVE

Praluent and Repatha backed for approval in US

Sanofi and Amgen remain in fierce competition in PCSK9 inhibitors

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

- PMLiVE

Rivals look to put pressure on Sanofi’s Lantus

Novo Nordisk and Lilly claim clinical benefitsover top-selling diabetes drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links